Compass Therapeutics to Present at the 13th Annual Wedbush PacGrow Healthcare Conference
August 02, 2022 08:00 ET
|
Compass Therapeutics
BOSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
Clinical Decision Support Systems (CDSS) Market Size is projected to reach USD 3.81 Billion by 2030, growing at a CAGR of 6.83%: Straits Research
July 26, 2022 12:20 ET
|
Straits Research
New York, United States, July 26, 2022 (GLOBE NEWSWIRE) -- Clinical knowledge management includes clinical decision support systems. It's a computer application that leverages EHRs to make...
Presented at SCCT - New Plaque Clinical Data Provides Additional Insights on Anatomy and Physiology in Clinical Decision Making for Patients
July 21, 2022 11:00 ET
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- HeartFlow, Inc., the leader in revolutionizing precision heart care, released two datasets utilizing its HeartFlow AI-based Plaque...
PointCross Releases eDataValidator for SDTM, ADaM, SEND, and Define.XML Conformance to Prevailing FDA, CDISC, and PMDA Rules
July 20, 2022 09:00 ET
|
PointCross Life Sciences
FOSTER CITY, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- PointCross Life Sciences announced today the full complement release of its eDataValidator™ (eDV) for validating SDTM, ADaM, SEND and...
AXIM Biotechnologies Publishes Study Highlighting Neutralizing Antibody Levels of Poor Vaccine Responders with a Third COVID-19 Vaccine Dose
July 12, 2022 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company, announced today their...
Enlivex Announces New Preclinical Data in Ovarian Cancer Showing a Substantial Survival Benefit when Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 31, 2022 08:00 ET
|
Enlivex Therapeutics Ltd
Stand-alone therapy with PD1 checkpoint inhibitors has shown limited efficacy against ovarian cancer, with response rates in prior clincical trials ranging from 7-15%. This contributes to poor patient...
COLORESCIENCE® REVEALS CLINICAL STUDY RESULTS OF THE FINISHING TOUCH™ SKINCARE PROTOCOL FOLLOWING FACIAL RADIOFREQUENCY MICRONEEDLING PROCEDURES
May 25, 2022 08:45 ET
|
Colorescience
Carlsbad, CA, May 25, 2022 (GLOBE NEWSWIRE) -- In the midst of Skin Cancer Awareness Month, Colorescience®, a leading dermatologist-recommended specialty skincare and cosmetics company announces...
Enlivex Awarded Its Third Non-Dilutive Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis Patients
May 25, 2022 08:00 ET
|
Enlivex Therapeutics Ltd
Grant provides $1.2 million in non-dilutive funding for 2022 sepsis clinical trial expensesTo date, Enlivex has received a total of $7.8 million in non-dilutive grants from the Israel Innovation...
Compass Therapeutics to Present at the 2022 H.C. Wainwright Annual Global Investment Conference
May 23, 2022 08:00 ET
|
Compass Therapeutics
BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
Compass Therapeutics to Present at the Bank of America Securities 2022 Healthcare Conference on Thursday, May 12, 2022 at 11:20 a.m. PT
May 05, 2022 08:00 ET
|
Compass Therapeutics
BOSTON, May 05, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...